Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""C. Maurer"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Autorzy:
    Maurer C; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Pflug N; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Bahlo J; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Kluth S; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Rhein C; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Cramer P; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Gross-Ophoff C; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Langerbeins P; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Fink AM; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Eichhorst B; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Kreuzer KA; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Fischer N; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
    Tausch E; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Böttcher S; Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
    Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
    Kneba M; Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
    Dreyling M; Department of Medicine III, Hospital of the University LMU München, München, Germany.
    Binder M; Department of Oncology and Hematology, BMT with Section Pneumology, Hubertus Wald Tumorzentrum/UVVH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    Hallek M; Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, Cluster of Excellence on 'Cellular Stress Responses in Aging' (CECAD), University of Cologne, Cologne, Germany.
    Wendtner CM; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
    Bergmann M; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
    Fischer K; Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
    Pokaż więcej
    Corporate Authors:
    German CLL Study Group
    Źródło:
    European journal of haematology [Eur J Haematol] 2016 Sep; Vol. 97 (3), pp. 253-60. Date of Electronic Publication: 2016 Feb 09.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Chromosome Aberrations ; Drug Administration Schedule ; Female ; Humans ; Lenalidomide ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Maximum Tolerated Dose ; Middle Aged ; Mutation ; Neoplasm Staging ; Prognosis ; Rituximab/administration & dosage ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes.
    Autorzy:
    Langerbeins P; Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne , Cologne , Germany.
    Maurer C
    Cramer P
    Eichhorst B
    Hallek M
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2015 Jun; Vol. 56 (6), pp. 1575-6. Date of Electronic Publication: 2015 May 12.
    Typ publikacji:
    Journal Article; Comment
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*adverse effects
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Leukemia, Myeloid, Acute/*chemically induced
    Myelodysplastic Syndromes/*chemically induced
    Neoplasms, Second Primary/*chemically induced
    Female ; Humans ; Male
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies